• Telix Pharmaceuticals appointed David Gill as board chair, effective immediately.
• Gill joined the board in May 2026 as a non-executive director.
• He is a life sciences executive with 35+ years’ experience across biopharma, radiopharmaceutical development, manufacturing, supply chain, medical devices.
• Gill previously served as CFO or president at EndoChoice Holdings, INC Research, CTI Molecular Imaging.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telix Pharmaceuticals Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608311821PRIMZONEFULLFEED9819029) on August 31, 2026, and is solely responsible for the information contained therein.